7:00 - 9:00 a.m.	Registration
8:30 a.m.	Continental Breakfast
9:00 a.m.	Welcome and Introductions William J. Martone, M.D. National Foundation for Infectious Diseases
	Keynote Address
9:10 a.m.	Promoting Vaccine Discovery: A Vision for the Future Robert F. Breiman, M.D. Centers for Disease Control and Prevention
9:50 a.m.	Questions and Answers
Symposium 1: Issues in Clinical and Field Trials: Design, Execution, and Analysis
	Moderator: Myron M. Levine, M.D., D.T.P.H. University of Maryland
10:00 a.m.	Experimental Challenge Models to Test the Efficacy of Enteric, Respiratory, and Other Vaccines in Volunteers -- Rationale, Advantages, and Limitations Carol O. Tacket, M.D. University of Maryland School of Medicine
10:30 a.m.	Questions and Answers
10:40 a.m.	Evaluating the Performance of New Vaccines: Efficacy vs. Effectiveness John D. Clemens, M.D. National Institutes of Health
11:10 a.m.	Questions and Answers
11:20 a.m.	Challenges in HIV Vaccine Development: Institutional Roles and Response Mary Lou Clements-Mann, M.D. The Johns Hopkins University
11:50 a.m.	Questions and Answers
12:00 p.m.	Lunch
Symposium 2: Correlates of Immunity: The Role of Surrogate Markers
	Moderator: David S. Krause, M.D. SmithKline Beecham Pharmaceuticals
1:30 p.m.	Introduction to Surrogate Markers David S. Krause, M.D. SmithKline Beecham Pharmaceuticals
1:40 p.m.	Lessons from the Past George R. Siber, M.D. Wyeth-Lederle Vaccines and Pediatrics
2:10 p.m.	A Regulatory Perspective Karen Midthun, M.D. U. S. Food and Drug Administration
2:40 p.m.	Panel Discussion
3:00 p.m.	Coffee Break
	Submitted Presentations 1
	DETERMINANTS OF INFLUENZA VACCINATION IN CHILDREN WITH ASTHMA IN FOUR HEALTH MAINTENANCE ORGANIZATIONS - Piotr Kramarz, M.D. IMMUNOGENICITY OF ATTENUATED DENGUE VIRUS VACCINES (PASTEUR MÉRIEUX CONNAUGHT, PMC) IN HUMAN VOLUNTEERS - N. Kanesa-Thasan BOOSTER DOSE HEPATITIS B IMMUNOGENICITY OF A PENTAVALENT [DTPw/HIB. MONOVALENT HEPATITIS B] VACCINE AT 18 MONTHS OF AGE FOLLOWING MONOVALENT HEPATITIS B VACCINE AT BIRTH, AND PENTAVALENT VACCINE AT 2, 4, AND 6 MONTHS - Terry Nolan ANTIPERTUSSIS ANTIBODIES OVER TIME AND PROTECTION AFTER HOUSEHOLD EXPOSURE TO BORDETELLA PERTUSSIS - Storsaeter, J ESTIMATING VACCINE EFFICACY WITH UNEQUAL FOLLOW-UP OF VACCINATED AND UNVACCINATED GROUPS - Phillip H. Rhodes RECRUITMENT FOR LARGE VACCINE TRIALS AT INDIVIDUAL INVESTIGATIVE SITES VAWNATED AND UNVACONATED GROUPS - W. Lang
3:00 p.m.	Coffee Break
Symposium 3: Maternal Immunization as a Strategy to Protect Offspring
	Moderator: Pamela M. McInnes, D.D.S. National Institutes of Health
3:30 p.m.	Maternal Immunization: Current Successes and Future Strategies Pamela M. McInnes, D.D.S. National Institutes of Health
3:40 p.m.	Immunological Aspects of Maternal Immunization Richard A. Insel, M.D. University of Rochester School of Medicine
4:10 p.m.	Maternal Immunization: The Two for One Group B Streptococcal Prevention Model Carol Baker, M.D. Baylor College of Medicine
4:40 p.m.	Maternal Immunization: Prevention of Respiratory Disease W. Paul Glezen, M.D. Baylor College of Medicine
5:10 pm	Panel Discussion
5:30 pm	Adjournment

8:00 a.m.	Continental Breakfast
Symposium 8: Vaccine Delivery Technologies: Beyond Needle and Syringe
	Moderator: Bruce G. Weniger, M.D. Centers for Disease Control and Prevention
8:30 a.m.	Overview: The Challenge to Immunization Practice by Increasing Numbers of Parenteral Vaccines Bruce G. Weniger, M.D. Centers for Disease Control and Prevention
8:35 a.m.	Mucosal Administration of Vaccine Antigens Pearay L. Ogra, M.D. Children's Hospital, University of Texas Medical Branch
9:00 a.m.	Questions and Answers
9:05 a.m.	Intranasal and Oral Delivery of Vaccines: Clinical Experience with Cold-Adapted Intranasal Influenza Robert Belshe, M.D. St. Louis University School of Medicine
9:30 a.m.	Questions and Answers
9:35 a.m.	Needle-Free Parenteral Jet Injection: Past, Present, and Future Glenn Austin Program for Appropriate Technology in Health (PATH)
10:00 a.m.	Questions and Answers
10:05 a.m.	Panel Discussion
10:30 a.m.	Coffee Break
	Submitted Presentations 4
	PRECLINICAL ASSESSMENT OF A NOVEL CLASS OF IMMUNOADJUVANTS - Louis Mercure TRANSCUTANEOUS IMMUNIZATION USING CHOLERA TOXIN AS ANTIGEN AND ADJUVANT INDUCŠS SYSTEMIC AND MUCOSAL RESPONSES AND PROVIDES IMMUNOPROTECTION - Gregory Glenn CPG MOTIFS ESTABLISH TH1 RESPONSES AND REDIRECT PRE-ESTABLISHED TH2 RESPONSES AGAINST HEPATITIS B - R. Weeratna CHARACTERIZATION OF IMMUNE RESPONSES STIMULATED BY COMBINATIONS OF OLIGOMERIC SGP140 AND TOXIN DERIVITIVES - Timothy R. Fouts
12:00 p.m.	Lunch
Symposium 9: Veterinary and Comparative Models of Disease and Protection
	Moderator: M.H.V. Van Regenmortel, Ph.D. Institut de Biologie Moleculaire et Cellulaire
1:30 p.m.	Analysis of Protective Immunity in FIV Margaret J. Hosie, Ph.D. University of Glasgow Veterinary School
2:00 p.m.	Antigenic Mimicry in Foot and Mouth Disease M.H.V. Van Regenmortel, Ph.D. Institut de Biologie Moleculaire et Cellulaire
2:30 p.m.	Nutritional Effects on Vaccination Mark E. Cook, Ph.D. University of Wisconsin at Madison
3:00 p.m.	Panel Discussion
3:30 p.m.	Adjournment
	Submitted Presentations 5
	PHASE I STUDY OF TWO DOSES OF MONOVALENT LIVE-ATTENUATED DENGUE VIRUS VACCINES - Wellington Sun MATERNAL ANTIBODIES PROVIDE PASSIVE IMMUNITY AND MODULATE ANTIBODY RESPONSES TO HUMAN ROTAVIRUS (HRV) IN GNOTOBIOTICS PIGS - L. Saif HLA-DPA 1 ALLELES AND MEASLES VACCINE ANTIBODY (AB) RESPONSE: PRELIMINARY RESULTS - I.G. Ovsyannikova ORAL IMMUNIZATION WITH HUMAN PAPILLOMAVIRUS TYPE 11 (HPV-11) RECOMBINANT VIRUS-LIKE PARTICLES (VLPS) INDUCES A POTENTIALLY PROTECTIVE SYSTEMIC IMMUNE RESPONSE IN MICE - Robert C. Rose PROTECTIVE ROLE OF ANTIBODIES ELICITED BY LIPOOLIGOSACCHARIDE BASED-CONJUGATE VACCINES OF MONOTYPABLE HAEMOPHILUS INFLUENZAE IN CHINCHILLA OTITIS MEDIA MODEL - J. Sun IDENTIFICATION OF A PEPTIDE MIMIC OF A PROTECTIVE EPITOPE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) - Daniel Chargelegue ANTIBODY-DEPENDENT CELL CYTOTOXICITY (ADCC) INHIBITS HIV REPLICATION - Donald N. Forthal
3:30 p.m.	Adjournment
	Poster Session A: Novel Vaccines and Novel Delivery Methods
	TOWARDS DEVELOPING AN HIV-1 VACCINE FOR INDIA: COMPUTER-DRIVEN PREDICTION AND ANALYSIS OF CTL EPITOPES - Jean-David Barnea DNA VACCINATION WITH CO-ADMINISTRATION OF CYTOKINES FOR PREVENTION OF HIV INFECTION - M. Bennett DNA VACCINATION AS IMMUNOTHERAPY FOR HIV INFECTION - A. Cohen PURIFIED RECOMBINANT MENIGICOCCAL NsPA PROTEIN INDUCES THE PRODUCTION OF CROSS-REACTIVE BACTERICIDAL AND PROTECTIVE ANTIBODIES IN MICE AND MONKEYS - B.R. Brodeur GENETIC IMMUNIZATION USING THE FLAA GENE CONFERS PARTIAL PROTECTION AGAINST HELIOBACTER PYLORI INFECTION IN GERM-FREE C57/BL6 MICE - R. Mankoski ADVANTAGES OF USING NOVEL CARRIER PROTEINS IN POLYSACCHARIDE CONJUGATES - M.S. Blake EFFECTIVE INDUCTION OF IMMUNE RESPONSE TO JAPANESE CEDAR PLLEN ALLEGEN (CRY J 1) IN MICE BY GENE GUN DNA DELIVERY SYSTEM - Masako Toda APPUCATION OF ANlIGEN-I.IPOSOME CONJUGATES TO VACCINE DEVELOPMENT - Tetsuya Uchida ORAL IMMUNIZATION WITH PLASMODIUM CHABAUDI-PARASITIZED RBC INDUCES EXPANSION OF B-1 CELLS - Brian J. Yoder MECHANISMS OF ANTIBODY PRODUCTION BY GUT-ASSOCIATED LYMPHOID TISSUES AFTER I.M. IMMUNIZTION WITH ROTOVIRUS - S.E. Coffin
	Poster Session B: Assessing Immunologic Response and Disease Protection I
	RESPONSE TO INFLUENZA VACCINE IN HIV-INFECTED INDIVIDUALS - F.A. Cruiekshank, M.D. IMMUNOGENICITY OF FDA VERSUS WHO DTP - Mohamed Khalil, M.B. Beh, M.Se., M.P.H., M.D. EFFECT OF ANNUAL INFLUENZA VACCINATION ON THE IMMUNOLOGlC RESPONSE IN THE ELDERLY - R. Ruttmann, EFFECT OF PRIOR VACCINATION ON ANTIBODY RESPONSES TO INACTIVATED INFLUENZA VACCINE IN YEARS WHEN VACCINE COMPONENTS CHANGE AND IN YEARS WITHOUT A CHANGE IN VACCINE COMPONENTS - J. Treanor EFFICACY AND EFFECTIVENESS OF INACTIVATED INFLUENZA VACCINE AMONG CHILDREN ATTENDING DAY CARE - Hurwitz, E.S. NEONATAL GROUP B STREPTOCOCCAL DISEASE: PROGRESS TOWARD A MULTIVALENT MATERNAL VACCINE - L.C. Paoletti SYSTEMIC IMMEDIATE-TYPE REACTIONS TO GELATIN INCLUDED IN VARICELLA AND JAPANESE ENCEPHALITIS (JE) VACCINES - Sakaguehi, M.

• Back to NFID-SPONSORED CONFERENCES